{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:16:28Z","timestamp":1794107788625,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114099"],"award-info":[{"award-number":["70114099"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bundeministerium f\u00fcr Gesundheit","award":["ZMV I 1 - 25 18 FSB 404"],"award-info":[{"award-number":["ZMV I 1 - 25 18 FSB 404"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2024,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cytokine release syndrome (CRS) is a significant side-effect of conventional chimeric antigen receptor (CAR) T-cell therapy. To facilitate patient accessibility, short-term (st) CAR T cells, which are administered to patients only 24\u2009h after vector exposure, are in focus of current investigations. Their impact on the incidence and severity of CRS has been poorly explored. Here, we evaluated CD19-specific stCAR T cells in preclinical models. In co-culture with tumor cells and monocytes, stCAR T cells exhibited anti-tumoral activity and potent release of CRS-related cytokines (IL-6, IFN-\u03b3, TNF-\u03b1, GM-CSF, IL-2, IL-10). When administered to NSG-SGM3 mice, stCAR T cells, but not conventional CAR T cells, induced severe acute adverse events within 24\u2009h, including hypothermia and weight loss, as well as high body scores, independent of the presence of tumor target cells. Human (IFN-\u03b3, TNF-\u03b1, IL-2, IL-10) and murine (MCP-1, IL-6, G-CSF) cytokines, typical for severe CRS, were systemically elevated. Our data highlight potential safety risks of rapidly manufactured CAR T cells and suggest NSG-SGM3 mice as sensitive model for their preclinical safety evaluation.<\/jats:p>","DOI":"10.1038\/s44321-024-00055-9","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T06:02:05Z","timestamp":1711000925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8224-5049","authenticated-orcid":false,"given":"Arezoo","family":"Jamali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6897-6785","authenticated-orcid":false,"given":"Naphang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Adabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-099X","authenticated-orcid":false,"given":"Frederic B","family":"Thalheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-7345","authenticated-orcid":false,"given":"Christian J","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"55_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B (2021) Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov 2:408\u2013422","journal-title":"Blood Cancer Discov"},{"key":"55_CR2","doi-asserted-by":"publisher","first-page":"e150807","DOI":"10.1172\/JCI150807","volume":"132","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, Bezzecchi E, El Khoury R, Norata R, Sanvito F et al (2022) CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Investig 132:e150807","journal-title":"J Clin Investig"},{"key":"55_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1182\/blood.V128.22.654.654","volume":"128","author":"DM Barrett","year":"2016","unstructured":"Barrett DM, Singh N, Hofmann TJ, Gershenson Z, Grupp SA (2016) Interleukin 6 is not made by chimeric antigen receptor T cells and does not impact their function. Blood 128:654","journal-title":"Blood"},{"key":"55_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.omtm.2021.02.013","volume":"21","author":"N Cordes","year":"2021","unstructured":"Cordes N, Kolbe C, Lock D, Holzer T, Althoff D, Sch\u00e4fer D, Blaeschke F, Kotter B, Karitzky S, Rossig C et al (2021) Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells. Mol Ther Methods Clin Dev 21:42\u201353","journal-title":"Mol Ther Methods Clin Dev"},{"key":"55_CR5","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood.V78.11.2791.bloodjournal78112791","volume":"78","author":"GD Demetri","year":"1991","unstructured":"Demetri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78:2791\u20132808","journal-title":"Blood"},{"key":"55_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","volume":"29","author":"SL Deshmane","year":"2009","unstructured":"Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29:313\u2013326","journal-title":"J Interferon Cytokine Res"},{"key":"55_CR7","doi-asserted-by":"publisher","first-page":"e003486","DOI":"10.1136\/jitc-2021-003486","volume":"10","author":"E Donnadieu","year":"2022","unstructured":"Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, Angelis BD, Choudhary R, Espie D, Galy A et al (2022) Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. J Immunother Cancer 10:e003486","journal-title":"J Immunother Cancer"},{"key":"55_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, Shen F, Cummins KD, Plesa G, Cantu VA et al (2022) Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng 6:118\u2013128","journal-title":"Nat Biomed Eng"},{"key":"55_CR9","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi S, Nunez-Cruz S, O\u2019Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F et al (2018) Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol Res 6:1100\u20131109","journal-title":"Cancer Immunol Res"},{"key":"55_CR10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24:731\u2013738","journal-title":"Nat Med"},{"key":"55_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7:1404\u20131419","journal-title":"Cancer Discov"},{"key":"55_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","volume":"13","author":"A Jamali","year":"2019","unstructured":"Jamali A, Kapitza L, Schaser T, Johnston ICD, Buchholz CJ, Hartmann J (2019) Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors. Mol Ther Methods Clin Dev 13:371\u2013379","journal-title":"Mol Ther Methods Clin Dev"},{"key":"55_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"key":"55_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C (2017) Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 4:92\u2013101","journal-title":"Mol Ther Methods Clin Dev"},{"key":"55_CR15","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl J Med 371:1507\u20131517","journal-title":"New Engl J Med"},{"key":"55_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22:85\u201396","journal-title":"Nat Rev Immunol"},{"key":"55_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00441-017-2763-0","volume":"371","author":"V Naumenko","year":"2018","unstructured":"Naumenko V, Turk M, Jenne CN, Kim S-J (2018) Neutrophils in viral infection. Cell Tissue Res 371:505\u2013516","journal-title":"Cell Tissue Res"},{"key":"55_CR18","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med 377:2531\u20132544","journal-title":"New Engl J Med"},{"key":"55_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P et al (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24:739\u2013748","journal-title":"Nat Med"},{"key":"55_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I et al (2018) Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 24:1499\u20131503","journal-title":"Nat Med"},{"key":"55_CR21","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","volume":"294","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva M, Duchateau P, Depil S, Poirot L, Valton J (2019) Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J Biol Chem 294:5430\u20135437","journal-title":"J Biol Chem"},{"key":"55_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1074-7613(02)00424-7","volume":"17","author":"CL Semerad","year":"2002","unstructured":"Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC (2002) G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 17:413\u2013423","journal-title":"Immunity"},{"key":"55_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jcyt.2017.04.001","volume":"19","author":"N Singh","year":"2017","unstructured":"Singh N, Hofmann TJ, Gershenson Z, Levine BL, Grupp SA, Teachey DT, Barrett DM (2017) Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 19:867\u2013880","journal-title":"Cytotherapy"},{"key":"55_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.omtm.2020.10.009","volume":"19","author":"M Soldi","year":"2020","unstructured":"Soldi M, Sergi Sergi L, Unali G, Kerzel T, Cuccovillo I, Capasso P, Annoni A, Biffi M, Rancoita PMV, Cantore A et al (2020) Laboratory-scale lentiviral vector production and purification for enhanced ex vivo and in vivo genetic engineering. Mol Ther Methods Clin Dev 19:411\u2013425","journal-title":"Mol Ther Methods Clin Dev"},{"key":"55_CR25","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.3390\/ijms21176347","volume":"21","author":"AA Stegelmeier","year":"2020","unstructured":"Stegelmeier AA, Chan L, Mehrani Y, Petrik JJ, Wootton SK, Bridle B, Karimi K (2020) Characterization of the impact of oncolytic vesicular stomatitis virus on the trafficking, phenotype, and antigen presentation potential of neutrophils and their ability to acquire a non-structural viral protein. Int J Mol Sci 21:6347","journal-title":"Int J Mol Sci"},{"key":"55_CR26","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM et al (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Investig 126:2123\u20132138","journal-title":"J Clin Investig"},{"key":"55_CR27","first-page":"630","volume":"133","author":"TR Ulich","year":"1988","unstructured":"Ulich TR, Del Castillo J, Souza L (1988) Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia. Am J Pathol 133:630\u2013638","journal-title":"Am J Pathol"},{"key":"55_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","volume":"53","author":"P Vormittag","year":"2018","unstructured":"Vormittag P, Gunn R, Ghorashian S, Veraitch FS (2018) A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol 53:164\u2013181","journal-title":"Curr Opin Biotechnol"},{"key":"55_CR29","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1038\/s41596-021-00510-8","volume":"16","author":"T Weidner","year":"2021","unstructured":"Weidner T, Agarwal S, Perian S, Fusil F, Braun G, Hartmann J, Verhoeyen E, Buchholz CJ (2021) Genetic in vivo engineering of human T lymphocytes in mouse models. Nat Protoc 16:3210\u20133240","journal-title":"Nat Protoc"},{"key":"55_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, He J, Zhang X, Li J, Wang Z, Zhang Y, Qiu L, Wu Q, Sun Z, Ye X et al (2022) Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J 12:104","journal-title":"Blood Cancer J"},{"key":"55_CR31","doi-asserted-by":"publisher","first-page":"12963","DOI":"10.1096\/fj.202001203R","volume":"34","author":"C Ye","year":"2020","unstructured":"Ye C, Yang H, Cheng M, Shultz LD, Greiner DL, Brehm MA, Keck JG (2020) A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic-related cytokine release syndrome. FASEB J 34:12963\u201312975","journal-title":"FASEB J"},{"key":"55_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00688-4","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, He J, Liu L, Wang J, Wang S, Liu L, Ge J, Gao L, Gao L, Kong P et al (2022) Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia. Blood Cancer J 12:96","journal-title":"Blood Cancer J"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00055-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:18:39Z","timestamp":1786029519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00055-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,15]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00055-9","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"27 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CJB and FBT are inventors of patents describing cell-type specific lentiviral vectors. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"12"}}